Nd:YAG laser vitreolysis and health-related quality of life in patients with symptomatic vitreous floaters

dc.contributor.authorGacimartín García, Begoña
dc.contributor.authorOrduna Magán, Carlos
dc.contributor.authorÁlvarez Peregrina, Cristina
dc.contributor.authorVilla Collar, César
dc.contributor.authorSánchez Tena, Miguel Ángel
dc.date.accessioned2021-05-14T18:06:33Z
dc.date.available2021-05-14T18:06:33Z
dc.date.issued2022
dc.description.abstractBackground: The treatment of floaters has consisted primarily of monitoring. The therapeutic approach is based on surgical removal or Nd:YAG laser treatment. The objective of this study was the assessment of the quality of life in patients treated with Nd:YAG laser for floaters. Methods: Single-center pretest-posttest design in a cohort of subjects treated with Nd-YAG laser with Ultra Q-Reflex technology. Health-related quality of life of the patients was measured before and after the intervention with the Visual Function Questionnaires VFQ-25 and VFQ-39. Anxiety level was measured with the State-Trait Anxiety Inventory. Visual acuity, contrast sensitivity, and safety parameters were also considered. Results: Thirty-four patients were included in the study. For the VFQ-25 baseline, the median was 73.05, interquartile range (19.25) versus a final median value of 93.76 (8.73) with p < 0.01. The baseline median for the extended version VFQ-39 was 74.60 (19.01) versus the final median of 95.01 (6.50) with p < 0.001. Regarding the anxiety, according to the STAI questionnaire, there were statistically significant differences between the baseline and the final conditions, with a baseline median of 38 (11) versus a final median of 18 (19); p < 0.001. When the analyses differentiated between patients with and without myopia, there were statistically significant differences for VFQ-25 and VFQ-39. Conclusions: This study shows an improvement in the health-related quality of life and a significant decrease in anxiety for patients that have undergone Nd: YAG Ultra-Q Reflex laser vitreolysis for floaters vaporization. The effect found is higher in myopic patients.spa
dc.description.filiationUEMspa
dc.description.impact1.7 Q4 JCR 2022spa
dc.description.impact0.595 Q2 SJR 2022spa
dc.description.impactNo data IDR 2022spa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationGarcía, B. G., Orduna Magán, C., Alvarez-Peregrina, C., Villa-Collar, C., & Sánchez-Tena, M. Á. (2022). Nd:YAG laser vitreolysis and health-related quality of life in patients with symptomatic vitreous floaters. European Journal of Ophthalmology, 32(2), 1143-1148. https://doi.org/10.1177/11206721211008036spa
dc.identifier.doi10.1177/11206721211008036
dc.identifier.issn1120-6721
dc.identifier.issn1724-6016
dc.identifier.urihttp://hdl.handle.net/11268/10050
dc.language.isoengspa
dc.peerreviewedSispa
dc.relation.publisherversionhttps://doi.org/10.1177/11206721211008036spa
dc.rights.accessRightsrestricted accessspa
dc.subject.unescoTecnología médicaspa
dc.subject.unescoCalidad de vidaspa
dc.subject.unescoOftalmologíaspa
dc.titleNd:YAG laser vitreolysis and health-related quality of life in patients with symptomatic vitreous floatersspa
dc.typejournal articlespa
dspace.entity.typePublication
relation.isAuthorOfPublication71cfccd7-8542-4727-925f-2c3cb6c051d2
relation.isAuthorOfPublicatione19cbc49-41e7-4085-8afe-3e6d6a1608eb
relation.isAuthorOfPublication410ff67b-2bce-4f68-97d9-5dcf8d7afc54
relation.isAuthorOfPublication.latestForDiscovery71cfccd7-8542-4727-925f-2c3cb6c051d2

Files